Transgenic mouse model

Nettelbeck DM, Jerome V, Muller R. Gene therapy designer promoters for tumour targeting. Trends Genet 2000 16 174-181. 

Massoud TF, Gambhir SS. Molecular imaging in living subjects seeing fundamental biological processes in a new light. Genes Dev 2003 17 545-580. 

Martin KJ. The interactions of transcription factors and their adaptors, coactivators and accessory proteins. Bioessays 1991 13 499-503. 

Ptashne M, Gann A. Transcriptional activation by recruitment. Nature 1997 386 569-577. 

Gaudreau L, Adam MA, Ptashne M. Activation of transcription in vitro by recruitment of the yeast RNA polymerase II holoenzyme. Mol Cell 1998 1 913 916. 

---

Rossi D, BrambiUa L, Valori CF, Crugnola A, Giaccone G, Capobianco R, Mangier M, Kingston AE, Bloc A, Bezzi P, Volterra A (2005) Defective tumor necrosis factor-alpha-dependent control of astrocyte glutamate release in a transgenic mouse model of Alzheimer disease. J Biol Chem 280 42088-42096... 

Lunzer MM, Yekkirala A, Hebbel RP, Portoghese PS (2007) Naloxone acts as a potent analgesic in transgenic mouse models of sickle cell anemia. Proc Natl Acad Sci USA 104 6061-6065... 

Hosken, N.A., Shibuya, K., Heath, A.W., Murphy, KM. and O Garra, A. (1995) The effect of antigen dose on CD4+ T cell phenotype development in an a(3 TCR-transgenic mouse model. Journal of Experimental Medicine 182, 1579-1584. 

Chen, L. and Zhuang, X. Transgenic mouse models of dopamine deficiency. Ann. Neurol. 54(Suppl. 6) S91-S102,2003. 

Collard, J.-F., Cote, F. and Julien, J.-P. Defective axonal transport in a transgenic mouse model of amyotrophic lateral sclerosis. Nature 375 61-64,1995. 

Kostic, V., Jackson-Lewis, V., de Bilbao, F., Dubois-Dauphin, M. and Przedborski, S. Bcl-2 prolonging life in a transgenic mouse model of familial amyotrophic lateral sclerosis. Science 277 559-562,1997. 

Turner, B. J., Lopes, E. C. and Cheema, S. S. Neuromuscular accumulation of mutant superoxide dismutase 1 aggregates in a transgenic mouse model of familial amyotrophic lateral sclerosis. Neurosci. Lett. 350 132-136, 2003. 

Transgenic mouse models are being used to test a variety of novel therapies, including ways of reducing secretase activities and decreasing Ap burden by Ap immunotherapy. Many experimental therapeutic efforts... 

Sturchler-Pierrat, C., Abramowski, D., Duke, M. et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. Nat. Acad. Sci. USA 94 13287-13292,1997. 

There are four transgenic mouse models that have been broadly evaluated the TSPpSB, the Tg.AC, the Hras2 and the XPA. Each of these has its own characteristics. Each of these merits some consideration. They are each made by either zygote injection or specific gene targeting in embryonic cells (McAnulty, 2000 French et al., 1999). 

McAnulty, PA. (2000). Transgenic Mouse models in carcinogenicity testing, European Pharmaceutical Contractor, July, 2000, pp. 84-90. 

Tennant, R.W., French, J.E. and Spalding, J.W. (1995). Identification of chemical carcinogens and assessing potential risks in short-term bioassays using transgenic mouse models. Environ. Health Perspect. 103 942-950. 

A novel thiophene-based molecular scaffold that could be used for optical in vivo imaging of protein aggregates was recently reported by Aslund et al. [36]. This chemically defined anionic pentameric thiophene derivative, p-FTAA (Fig. 21a), could be utilized for direct in vivo detection of A [S deposit in the brain of a transgenic mouse model with AD pathology. The deposits were easily visualized by two-photon... 

Janus, C., Chishti, M.A., and Westaway, D., Transgenic mouse models of Alzheimer s disease, Biochim. Biophys. Acta, 1502, 63, 2000. 

Gardian G, Browne SE, Choi DK, KUvenyi P, Gregorio J, Kubilus JK, Ryu H, Langley B, Ratan RR, Ferrante RJ, Beal ME (2005) Neuroprotective effects of phenylbutyrate in the N171-824 transgenic mouse model of Huntington s disease. J Biol Chem 280(l) 556-563... 

---